THE WHAT? Aesop and The Body Shop parent company Natura has reported a slight sales decline in Q3, with consolidated net revenue in at R$9.5 billion, down 4.2 percent in BRL and 4.5 percent at constant currency.
THE DETAILS However, the beauty giant posted strong growth in the first nine months of the year and compared to Q3 two years ago, prior to the onset of the pandemic. On a YOY basis, net income improved by over $1 Billion Reais.
Digitally-enabled sales, including online, reached 52 percent of the company’s total revenue for Q3.
Natura &Co’s Latam net revenue decreased 2.4 percent in BRL during Q3, however, was up 14.4 percent over nine months. Avon International’s net revenue decreased 14.3 percent in Q3 but was up 6.3 percent in the first nine months, while Natura’s brand power ‘reached its highest level.’
The Body Shop posted a ‘solid performance,’ with net revenue up 0.4 percent in BRL in the quarter and 20.6 percent in the nine months
According to a press release, “Over the first nine months of the year, net revenue was R$28.5 billion, up 14.4% vs the same period last year in Brazilian Reais (+8% at constant currency), adjusted EBITDA margin stood at 9.1% (-190 basis points) and net income reached R$352.6 million, reversing a loss in the year-ago period of R$827.6 million.”
Natura has also announced it is launching a share price of R$ 1.5 billion, and is considering switching primarily to the NYSE to highlight its increasingly global nature, while maintaining a dual listing with Brazilian Depositary Receipts (BDRs) in Brazil.
THE WHY? Roberto Marques, Executive Chairman and Group CEO, said, “Despite a very tough comparable vs last year, when we grew over 20 percent, and some persistent external headwinds related to the global pandemic, Natura &Co continues to progress on its key initiatives, attesting to the underlying strength of our business. We again outperformed the global Cosmetics, Toiletries and Fragrances market on a year-to-date basis and versus pre-pandemic levels, all our brands and businesses posted growth over nine months and the Group’s digitalization continued to advance.”
Aesthetic medicine products are developed and regulated to meet stringent safety and efficacy standards. They are typically administered by trained healthcare professionals such as dermatologists, plastic surgeons, and specialized nurses in clinical settings. These products aim to provide effective solutions for cosmetic enhancement, skin rejuvenation, and overall aesthetic improvement, contributing to both physical appearance and self-confidence.
Key categories of aesthetic medicine products include:
-
Injectables: This category includes products such as dermal fillers, botulinum toxins (e.g., Botox), and collagen stimulators. These injectables are used to smooth wrinkles, add volume, and improve facial contours.
-
Skin Rejuvenation Treatments: Products like chemical peels, microdermabrasion systems, and laser devices are used to improve skin texture, reduce pigmentation irregularities, and enhance overall skin tone.
-
Skincare Products: These include medical-grade cleansers, moisturizers, serums, and topical treatments containing active ingredients like retinoids, antioxidants, and growth factors. They are formulated to address specific skin concerns such as acne, aging, and hyperpigmentation.
-
Hair Restoration Products: Medical treatments and products designed to promote hair growth and treat conditions such as male and female pattern baldness.
-
Body Contouring and Fat Reduction: Devices and products used for non-surgical body sculpting, such as cryolipolysis (cool sculpting) devices and injectable lipolytics.
-
Cosmeceuticals: High-performance skincare products that bridge the gap between cosmetics and pharmaceuticals, often containing potent ingredients with proven clinical benefits.
-
Wound Care and Scar Management: Products like silicone sheets, gels, and advanced wound dressings used to improve healing and reduce the appearance of scars.
